Corcept Therapeutics (CORT) Stock Price, News & Analysis

Company Overview

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Beyond Korlym, Corcept is advancing a proprietary pipeline of selective glucocorticoid receptor modulators, most notably relacorilant. Relacorilant is under investigation in multiple clinical trials for indications including endogenous Cushing’s syndrome, platinum-resistant ovarian cancer and psychotic major depression, reflecting Corcept’s commitment to expanding therapeutic options where cortisol dysregulation plays a key role.

Founded in 1998 and headquartered in Redwood City, California, Corcept went public in 2012 to support its transition from research to commercialization. Since then, the company has built a specialized commercial organization in the United States and is pursuing regulatory filings and partnerships in Europe and other regions. Corcept collaborates with academic institutions, clinical research centers and regulatory authorities to advance its programs from proof of concept through pivotal trials.

Corcept is led by President and CEO Joseph K. Belanoff, M.D., who co-founded the company and has guided its scientific and strategic direction for more than two decades. Under his leadership, Corcept has established a multidisciplinary team of researchers, clinicians and commercial experts. The company continues to explore novel approaches to glucocorticoid receptor modulation with the goal of delivering transformative therapies for patients affected by debilitating cortisol-related disorders.

Key Stats

• Today's Range: $73.12 to $87.54
• 50-Day Range: $68.82 to $90.32
• 52-Week Range: $42.01 to $117.33
• Volume: 2.28 million shs
• Average Volume: 955,065 shs
• Market Capitalization: $7.79 billion
• P/E Ratio: 65.45
• Dividend Yield: N/A
• Price Target: $135.25
• Consensus Rating: Moderate Buy

Corcept Therapeutics Stock Analysis - MarketRank™

Corcept Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 28th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Corcept Therapeutics has a consensus price target of $135.25, representing about 82.9% upside from its current price of $73.96.

Amount of Analyst Coverage

Corcept Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 36.03%

Earnings Growth

Earnings for Corcept Therapeutics are expected to grow by 36.03% in the coming year, from $1.36 to $1.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corcept Therapeutics is 65.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 230.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corcept Therapeutics is 65.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.27.

Price to Book Value per Share Ratio

Corcept Therapeutics has a P/B Ratio of 11.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.59% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Corcept Therapeutics has recently decreased by 0.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corcept Therapeutics does not currently pay a dividend.

Dividend Growth

Corcept Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.07

Percentage of Shares Shorted

11.59% of the float of Corcept Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Corcept Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Corcept Therapeutics has recently decreased by 0.64%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.54

News Sentiment

Corcept Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Corcept Therapeutics this week, compared to 15 articles on an average week.

Search Interest

36 people have searched for CORT on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.

MarketBeat Follows

5 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,713,516.00 in company stock.

Percentage Held by Insiders

20.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CORT Stock Analysis - Frequently Asked Questions

How have CORT shares performed this year?

Corcept Therapeutics' stock was trading at $50.39 at the beginning of 2025. Since then, CORT shares have increased by 46.8% and is now trading at $73.96.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings data on Thursday, July, 31st. The biotechnology company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. The business's revenue was up 18.7% on a year-over-year basis.
Read the conference call transcript.

Who are Corcept Therapeutics' major shareholders?

Top institutional investors of Corcept Therapeutics include Voya Investment Management LLC (0.03%), Ausbil Investment Management Ltd (0.01%), GAMMA Investing LLC and Wedmont Private Capital. Insiders that own company stock include Joseph K Belanoff, Hazel Hunt, Gary Charles Robb, Joseph Douglas Lyon, Sean Maduck, William Guyer, David L Mahoney, Daniel N Swisher, Jr and Daniel N Swisher Jr.
View institutional ownership trends.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CORT
• CIK: 1088856
• Web: www.corcept.com
• Phone: (650) 327-3270
• Fax: 650-327-3218
• Employees: 300
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Corcept Therapeutics: $135.25
• High Price Target: $145.00
• Low Price Target: $121.00
• Potential Upside/Downside: +82.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.13
• Trailing P/E Ratio: 65.45
• Forward P/E Ratio: 54.38
• P/E Growth: N/A
• Net Income: $141.21 million
• Net Margins: 18.51%
• Pretax Margin: 17.63%
• Return on Equity: 20.10%
• Return on Assets: 16.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.06
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $675.04 million
• Price / Sales: 11.54
• Cash Flow: $1.04 per share
• Price / Cash Flow: 71.14
• Book Value: $6.49 per share
• Price / Book: 11.40

Miscellaneous

• Outstanding Shares: 105,370,000
• Free Float: 83,455,000
• Market Cap: $7.79 billion
• Optionable: Optionable
• Beta: 0.46